Plasma Brain-Derived Neurotrophic Factor as a Peripheral Marker for the Action Mechanism of Antidepressants

Hwa-Young Lee\textsuperscript{a}  Yong-Ku Kim\textsuperscript{b, c}

\textsuperscript{a}Department of Psychiatry, College of Medicine, Korea University Anam Hospital, \textsuperscript{b}Division of Brain Korea 21 Biomedical Science, Korea University, Seoul, and \textsuperscript{c}Department of Psychiatry, College of Medicine, Korea University Ansan Hospital, Ansan, Korea

Key Words
Brain-derived neurotrophic factor \cdot Major depressive disorder \cdot Antidepressant treatment

Abstract
Numerous studies have demonstrated that depression is associated with a decreased expression of brain-derived neurotrophic factor (BDNF). BDNF shows antidepressant-like effects in animal models. Therefore, we tested the hypothesis that BDNF might be a peripheral marker for the mechanism of action of antidepressant agents in humans. Thirty-two patients meeting the DSM-IV criteria for major depressive disorder and 50 normal control subjects were recruited for this study. Plasma BDNF levels and Hamilton Depression Rating Scales were measured at baseline and 6 weeks after antidepressant administration. At baseline, the mean plasma BDNF level was lower in the depressive patients (698.1 $\pm$ 537.7 pg/ml) than in the control subjects (830.7 $\pm$ 624.8 pg/ml), although the difference was not statistically significant ($p = 0.33$). The plasma BDNF levels in depressive patients significantly increased from 698.1 $\pm$ 537.7 to 1,028.9 $\pm$ 744.5 after 6 weeks of antidepressant treatment ($p = 0.01$). Moreover, plasma BDNF levels were significantly increased after 6 weeks of treatment in the responder group, while there was no statistically significant change in the unresponsive group. These results suggest that the therapeutic response after antidepressant administration might be attributable to the increase in BDNF levels. BDNF may play a critical role in the action mechanism of antidepressant drugs. Further studies with a larger number of subjects are needed to verify these findings.

Introduction
Brain-derived neurotrophic factor (BDNF), an important member of the neurotrophin family, is abundant in the brain and peripheral nervous system. It has many effects on the nervous system, such as neuronal growth, differentiation, and repair [1].

It has been shown that stress decreases the synthesis of hippocampal BDNF in adult animals [2, 3] and induces atrophy of the apical dendrites of CA3 neurons [4–6]. Growing evidence suggests that BDNF may play a crucial role in mental disorders such as Alzheimer’s disease [7], schizophrenia [8, 9], and especially depression [10–13]. So far, considerable work on the involvement of neurotrophic factors in the pathophysiology of depression has been carried out. Direct infusion of BDNF into the rat midbrain has antidepressant effects in the learned helplessness and forced swim behavioral models of depression in rodents [12]. In addition, long-term antidepressant drug treatment and electroconvulsive therapy can increase BDNF expression [14].
Although recent decades have witnessed a tremendous revolution in the development of antidepressant drugs, the neurochemical effects that underlie the therapeutic action of these agents remain largely unknown. Antidepressant drugs acutely increase levels of monoamines, but it takes 2–3 weeks to show a clinical response after the administration of an antidepressant drug [15], and the initial response rate in patients with major depressive disorders is about 70% [16]. These observations suggest that alterations in monoamine metabolism alone cannot explain the entire antidepressant effect. In this respect, it was suggested that the mechanism of action might be associated with intracellular signal transduction pathways that are linked to the expression of specific genes [17]. The neural plasticity hypothesis proposes that depression results from an inability to make appropriate adaptive responses to stress [18]. By stimulating intracellular pathways, antidepressants lead to upregulation of cAMP response element-binding (CREB) protein and an increase in the expression of neurotrophic factors, particularly BDNF. Based on the neuroplasticity hypothesis, plasma BDNF levels are necessarily increased by antidepressant action. The increase in BDNF by antidepressant treatment has been confirmed by a number of studies from many different laboratories. There have been, however, some inconsistent reports with certain classes of antidepressants, dosages of antidepressants, and the time of measurement after antidepressant administration [19, 20]. Moreover, most previous studies were performed to measure changes in BDNF levels after antidepressant administration, but without subdividing the patients according to responsiveness. In this study, therefore, we aimed to determine whether there is a difference in the change of BDNF levels between responsive and unresponsive patients before and after antidepressant administration.

Methods

Subjects

Thirty-two patients diagnosed with a major depressive disorder according to DSM-IV criteria were recruited from patients who visited Korea University Medical Center Ansan Hospital between March 2002 and July 2005. None of the depressive patients had taken psychotropic medications within the previous 2 weeks. During the study, concomitant medications such as benzodiazepine were permitted. Three of the depressive patients had attempted suicide at the time of their diagnosis. The control subjects consisted of 50 randomly selected healthy individuals who visited Korea University Ansan hospital for regular health screenings. The control subjects were closely matched with the depressive patient group in terms of age and sex. Control subjects were excluded if they had any self-reported personal or familial psychiatric history or psychotropic medication history, or if they had scores ≥10 on the Beck Depression Inventory or ≥40 on the State-Trait Anxiety Inventory. The study protocol was approved by the Ethics Committee of Korea University, and written informed consent was obtained from all patients and control subjects.

Clinical Evaluation

The severity of depressive symptoms was also evaluated using Hamilton’s 17-item depression rating scale [21]. Individuals were evaluated independently by 2 trained psychiatrists. The evaluations consisted of reviews of psychiatric and medical histories, evaluations of current and previous medication and alcohol intake, and semi-structured interviews for the purpose of establishing DSM-IV criteria diagnosis. Because BDNF expression in the central nervous system is modified in diabetes mellitus, epilepsy, addiction disorders, and eating disorders, patients with these diseases were excluded from this study. Diagnoses and ratings were decided by mutual consent (blind to plasma BDNF levels).

In the present study, various antidepressants were used according to the patient’s symptoms and tolerance, including paroxetine (7 patients, average dose: 28.6 mg), citalopram (16 patients, average dose: 30.6 mg), and venlafaxine (10 patients, average dose: 150.0 mg).

To group the patients by responsiveness, responders were defined as those patients who had a decrease of at least 50% in their HDRS total score between baseline and 6 weeks after antidepressant treatment.

Blood Sample Collection

For depressive patients and control subjects, blood samples were drawn from the subjects’ antecubital veins at the same time of the morning following an overnight fast. Approximately 10 ml of blood was collected and placed in a lithium heparin vacuum tube.

Plasma BDNF Measurement

All blood samples were immediately centrifuged at 3,800 rpm for 10 min. Plasma was stored at −70°C until it was thawed for assay. Human BDNF was assayed by using the DuoSet ELISA Development System (R&D Systems, cat No. DY248). All assays were performed in duplicate using the manufacturer’s recommended buffers, diluents, and substrates. In brief, the capture antibody was diluted to the final concentration (2 μg/ml) in phosphate-buffered saline (PBS), and 100 μl of diluted capture antibody was immediately put into a 96-well plate. The plate was sealed and incubated overnight at room temperature. The next morning, the wells were washed 3 times with PBS containing 0.05% Tween-20 (PBST). After the addition of 1% BSA and 5% sucrose (300 μl/well), the plate was incubated for 2 h at room temperature and again washed 3 times with PBST. The standards and samples were pipetted at 100 μl per well and allowed to incubate for 2 h at room temperature, then washed 3 times with PBST. After removing the entire buffer from the wash, 100 μl of dilution antibody (25 ng/ml in diluent) was added to each well. This was incubated for 2 h at room temperature and then washed 3 times with PBST. Then, 100 μl of diluted streptavidin-conjugated horse-
radish peroxidase was added to each well, incubated for 20 min at room temperature, and washed 3 times with PBST. Following the final washing procedure, 100 μl of substrate solution (R&D systems, cat No. DY999) was added to each well and then incubated for 20 min at room temperature. The reaction was terminated with 50 μl of 2 N sulfuric acid. The optical density of the color reaction in the wells was read using a microtiter plate reader (Biotek Instruments) set for 450 nm. The intra- and interassay coefficients of variation were below 10%. The concentrations of the samples in each plate were calculated according to a standard curve.

Statistical Analysis
All statistical analyses were performed with SPSS version 12.01 for Windows. The Pearson χ² test was used for testing the categorical variables, such as sex or diagnosis. Group mean differences were ascertained by means of Student’s t test, paired t test, and Mann-Whitney test. The Wilcoxon signed-ranks test was used to compare the BDNF levels before and after antidepressant administration in the non-responder group. Statistical significance was accepted if the two-tailed probability was less than 0.05.

Results

Characteristics of the Subjects
Table 1 shows the demographic and clinical characteristics of both depressive patients and control subjects. There were no statistically significant differences between depressive patients and control subjects with respect to age (p = 0.57), gender (p = 0.21), weight (p = 0.25), or BMI (p = 0.87). At 6 weeks after treatment, there was a significant decrease in the HDRS scores from baseline in the depressive patients, and 24 subjects were placed in the responder group and 8 in the non-responder group. Regarding age, gender, age of onset, duration of illness, number of psychiatric hospitalizations, and baseline HDRS score, there were no significant differences between the responder and non-responder groups.

Comparison of Plasma BDNF Levels between Depressive Patients and Control Subjects
At baseline, the mean plasma BDNF level was lower in depressive patients (698.1 ± 537.7 pg/ml) than in the control subjects (830.7 ± 624.8 pg/ml), but the difference was not statistically significant (p = 0.33). Baseline plasma BDNF levels in non-responders were not significantly lower than those of controls in the present study (p = 0.20).

Comparison of Plasma BDNF Levels after 6 Weeks of Antidepressant Treatment
The plasma BDNF levels in depressive patients significantly increased from 698.1 ± 537.7 to 1,028.9 ± 744.5 after 6 weeks of antidepressant treatment (p = 0.01, data not shown). Moreover, in the responder group, plasma BDNF levels had increased from 733.0 ± 512.2 to 1,153.6 ± 766.0 pg/ml after antidepressant treatment (p < 0.01; fig. 1). There was, however, no significant change after

Table 1. Demographic and clinical characteristics of the subjects

<table>
<thead>
<tr>
<th></th>
<th>Control subjects (n = 50)</th>
<th>Depressive patients (n = 32)</th>
<th>p values (control vs. all)</th>
<th>p values (responders vs. non-responders)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>all (n=32)</td>
<td>responders (n = 24)</td>
<td>non-responders (n =8)</td>
</tr>
<tr>
<td>Age, years</td>
<td>38.5 ± 9.7</td>
<td>44.2 ± 17.3</td>
<td>46.6 ± 16.7</td>
<td>36.6 ± 17.6</td>
</tr>
<tr>
<td>Sex, n</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>24</td>
<td>11</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Female</td>
<td>26</td>
<td>21</td>
<td>16</td>
<td>5</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>58.8 ± 11.1</td>
<td>55.7 ± 11.0</td>
<td>53.9 ± 11.5</td>
<td>61.6 ± 6.0</td>
</tr>
<tr>
<td>Body mass index</td>
<td>22.1 ± 2.9</td>
<td>22.3 ± 3.9</td>
<td>21.5 ± 4.1</td>
<td>23.7 ± 3.3</td>
</tr>
<tr>
<td>Age at onset, years</td>
<td>n/a</td>
<td>40.1 ± 16.9</td>
<td>42.6 ± 15.7</td>
<td>33.5 ± 19.0</td>
</tr>
<tr>
<td>Duration of illness, months</td>
<td>n/a</td>
<td>46.2 ± 8.9</td>
<td>58.0 ± 96.7</td>
<td>10.3 ± 9.7</td>
</tr>
<tr>
<td>Psychiatric hospitalizations, n</td>
<td>n/a</td>
<td>0.56 ± 0.91</td>
<td>0.62 ± 0.88</td>
<td>0.38 ± 1.06</td>
</tr>
<tr>
<td>HDRS, baseline score</td>
<td>n/a</td>
<td>29.6 ± 8.4&lt;sup&gt;c&lt;/sup&gt;</td>
<td>29.4 ± 8.6</td>
<td>29.9 ± 7.9</td>
</tr>
<tr>
<td>HDRS, 6-week score</td>
<td>n/a</td>
<td>8.8 ± 8.0&lt;sup&gt;c&lt;/sup&gt;</td>
<td>5.0 ± 4.1</td>
<td>20.3 ± 5.2</td>
</tr>
<tr>
<td>Plasma BDNF (baseline), pg/ml</td>
<td>830.7 ± 624.8</td>
<td>698.1 ± 537.7</td>
<td>733.0 ± 512.2</td>
<td>593.5 ± 634.0</td>
</tr>
</tbody>
</table>

Values presented as means ± SD. n/a = Not applicable.
<sup>a</sup> Independent samples t test; <sup>b</sup> Mann-Whitney test; <sup>c</sup> Paired samples t test (p < 0.01); <sup>d</sup> χ² test; <sup>e</sup> Fisher’s exact test.
antidepressant treatment in the non-responder group (from 593.5 ± 634.0 to 654.7 ± 559.8 pg/ml; p = 0.83; fig. 1). After 6 weeks of treatment, a stronger tendency for plasma BDNF levels to increase was shown in the responder group (1,153.6 ± 766.0 pg/ml) compared to the non-responder group (654.7 ± 559.8 pg/ml; p = 0.08).

Discussion

We demonstrated that plasma BDNF levels increased significantly in depressive patients after antidepressant administration. Moreover, the increase in plasma BDNF levels was found in the responder group but not in the non-responder group. In a human post-mortem study, increased BDNF expression in hippocampal tissue was observed in antidepressant-treated depressive patients [13]. Similarly, pre-clinical studies have demonstrated that BDNF is associated with antidepressant treatment [12, 14, 22]. In clinical studies, Shimizu et al. [23] demonstrated that serum BDNF levels were significantly lower in an antidepressant-naïve depressive group than in either an antidepressant-treated depressive group or a control group. Because the antidepressant-naïve and antidepressant-treated patients were not the same subjects in that study [23], however, it was not possible to compare BDNF levels at baseline with levels after antidepressant administration. Aydemir et al. [24] showed that treatment for 12 weeks with venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), significantly increased serum BDNF levels in patients with a major depressive disorder. In this study, BDNF levels in the treated patients improved to the levels detected in control subjects. It was also reported that treatment with 10 mg/day of S-citalopram, a selective serotonin reuptake inhibitor (SSRI), for 6 weeks significantly increased serum BDNF levels in patients with a major depressive disorder [25]. After SSRI or SNRI administration, serum BDNF levels in depressed patients are significantly increased [26, 27]. In addition, Gönul et al. [27] reported that no difference was seen in the serum BDNF levels of patients receiving SSRI or venlafaxine, a SNRI. In a study restricted to female patients, the post-treatment BDNF levels of depressive patients were significantly higher than the pre-treatment levels after 6 weeks of treatment and were similar to the levels seen in control subjects [25, 28]. Yoshimura et al. [29] reported that patients responding to treatment with paroxetine (an SSRI) and milnacipran (an SNRI) for 8 weeks saw serum BDNF levels significantly increase to the same levels as the control group, but serum BDNF levels in non-responders did not increase. This finding is in agreement with the present study, suggesting that BDNF may be regarded as a peripheral marker for the action mechanism of antidepressant drugs [30]. Based on the neuroplasticity theory, BDNF is important to maintaining synaptic function and neural plasticity. In the presence of impaired neural plasticity, depression occurs. Antidepressant drugs may reverse depression due to

BDNF Levels and Antidepressants

Neuropsychobiology 2008:57:194–199
their ability to activate genes that encode neurotrophic factors [31, 32].

In accordance with previous studies [23–27, 33], baseline plasma BDNF levels were lower in the depressive patients than in normal controls, although there was no statistical significance in this study. The possible reasons for non-significance are as follows. First, the greater body weight of normal controls compared to depressive patients could contribute to non-significance because BDNF levels in plasma decrease with increasing weight [34]. Second, a greater proportion of females in the depressive patients could be a cause of non-significance due to changes in BDNF levels during the menstrual cycle [34]. Third, the small sample size and a high variance of plasma BDNF levels could be a major cause of the non-significance.

We tested the possibility of using BDNF plasma levels as a prodromic marker of non-response by comparing the BDNF plasma levels of the non-responder group to those of the controls. Baseline BDNF plasma levels of non-responders were not significantly lower than those of the controls in the present study (p = 0.20). The lack of significant differences in baseline BDNF plasma levels between non-responders and controls suggests that baseline BDNF levels might not be a prodromic marker of non-response.

The fact that the relation between plasma and brain BDNF levels is not very clear should also be noted. A major limitation of studies of plasma is that it is difficult to determine the significance of BDNF that is outside the blood-brain barrier. Most BDNF in the blood is stored in platelets [35], and one physiological study reported the free passage of intact BDNF across the blood-brain barrier by a high-capacity and saturable transport system as well as the efflux of BDNF from the brain to the blood [36]. Several studies have observed a positive correlation between serum and cortical levels of BDNF, indicating that the peripheral measurement of BDNF could be used as a surrogate measure for BDNF levels in the central nervous system [33, 37]. There is a large amount of evidence that other peripheral growth factors influence central nervous system function [38, 39]. Piccinni et al. [40] reported that, while the plasma BDNF levels increased to the values found in control subjects in parallel with the clinical improvement, antidepressant treatments did not induce any change in serum BDNF levels, which remained lower than those found in the control group at all assessment times (1st, 3rd, 6th, 12th month). Thereafter, they suggest, while plasma BDNF would behave as a state-dependent marker, serum BDNF might represent a trait of illness. Similarly, considering the interactions among plasma, platelets, and the blood-brain barrier [34–36], plasma BDNF levels may reflect brain BDNF levels.

Some other limitations of this study are as follows. First, due to the lack of a placebo group, we could not exclude the changes in BDNF levels that occurred in the course of illness. It is not possible to know to what degree the responses of the responders were due to the placebo effect versus pure antidepressant effect. Second, the present study had a very small sample size and included 3 suicidal subjects (2 drug intoxications and 1 deep laceration in the wrist). Suicide attempts can induce confounding effects [41]. Third, various kinds of antidepressants (SSRI, SNRI) were used in unblinded conditions, thus, creating heterogeneous treatment exposures. Therefore, the effects of different antidepressants on BDNF levels should be considered. There have been some inconsistent reports with respect to certain classes of antidepressants [19, 20]. Many studies, however, show no difference between the BDNF levels of patients receiving SSRI or SNRI [27, 29]. Moreover, although antidepressants are classified on the basis of their immediate actions on neurotransmitter receptors and enzymes, attention is increasingly being focused on how these immediate actions translate into delayed actions [31].

In conclusion, these results suggest that the therapeutic response after antidepressant administration is possibly related to the increase in BDNF levels, consistent with the neuroplasticity hypothesis. Given the complexity of both the physiological and pharmacological regulation of BDNF, it may be too simplistic to hypothesize that we would be able to identify the role of BDNF in the mechanism of action of antidepressant agents by examining the changes in plasma BDNF levels before and after antidepressant administration. Therefore, this study suggests a possible association between changes in BDNF levels and the therapeutic response to treatment. Further studies investigating the reason that BDNF levels are not increased after antidepressant administration in some patients, and more controlled studies with a larger number of subjects, may help to improve the rate of response to antidepressant therapy.

Acknowledgement

This study was supported by a grant from Korea University.
References